Class action lawsuits
Purchasers of Replimune securities between November 22, 2024, and July 21, 2025, may be entitled to compensation due to allegedly false and misleading statements made by the company's defendants. The securities class action lawsuit, filed by the Rosen Law Firm, claims that the defendants recklessly overstated the prospects
Class action lawsuits
A recent announcement by Novo Nordisk terminating its collaboration with Hims & Hers due to "deceptive" marketing of Wegovy(R) has triggered securities class action lawsuits against the company. Hagens Berman, a national shareholders rights firm, is investigating the claims and urges Hims & Hers investors who suffered
Class action lawsuits
A national plaintiffs' law firm has filed a class action lawsuit against Novo Nordisk A/S, alleging that the pharmaceutical company understated the impact of the personalization exception to the compounded GLP-1 exclusion, thereby overstating its ability to sustain long-term growth. The lawsuit claims that Novo Nordisk overstated the
Class action lawsuits
Hims & Hers Health, a telehealth platform company, is facing a lawsuit alleging potential securities law violations. The complaint, filed by securities law firm Bleichmar Fonti & Auld LLP, asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who
Class action lawsuits
Sarepta Therapeutics, a leading biotech company, has been rocked by a major restructuring announcement and a securities class action lawsuit alleging the company misled investors about the safety and efficacy of its flagship gene therapy, ELEVIDYS. The lawsuit, filed on behalf of investors, claims Sarepta withheld crucial information about significant
Class action lawsuits
Purchasers of Alto Neuroscience, Inc. common stock, including those who bought shares during or after the company's initial public offering (IPO) in February 2024, may be eligible for compensation due to allegedly false and misleading statements made by the company regarding its business and clinical prospects. The lawsuit
Class action lawsuits
Bronstein, Gewirtz & Grossman, LLC has notified investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) and certain of its officers. The lawsuit alleges that defendants made material false and misleading statements regarding the company's initial public offering and the effectiveness of
Class action lawsuits
A securities class action lawsuit has been filed against Rocket Pharmaceuticals, a biotechnology company developing gene therapies for rare diseases, alleging that the company misled investors about the safety and progress of its critical RP-A501 gene therapy trial for Danon disease. The lawsuit centers on whether Rocket provided materially false
Class action lawsuits
A securities class action lawsuit has been filed against Lockheed Martin Corporation (LMT) alleging that the company made false and misleading statements regarding its financial performance and contracts. The lawsuit, styled Khan v. Lockheed Martin Corporation, et al., seeks to represent investors who purchased or acquired Lockheed Martin securities between
Class action lawsuits
A securities class action lawsuit has been filed against Lockheed Martin Corporation alleging that the company engaged in securities fraud between January 23, 2024, and July 21, 2025. The lawsuit claims that Lockheed Martin made false statements about its internal controls, program requirements, and contract commitments, leading to significant losses
Class action lawsuits
Investors who purchased or acquired Lockheed Martin securities between January 23, 2024, and July 21, 2025, may be eligible to join a class action lawsuit alleging violations of federal securities laws. The lawsuit claims that during this period, Lockheed Martin made false and misleading statements about its business, operations, and
Class action lawsuits
Centene Corporation faced a class action securities lawsuit after allegedly providing false and misleading statements to investors about the company's enrollment and morbidity rates. The lawsuit claims that defendants concealed material adverse facts, including lower-than-expected market growth, which led to a significant decline in stock price. Investors who
